Primordial follicles remaining in young cancer survivors who received chemotherapy
Journal of Obstetrics and Gynaecology Research · 2023
DOI: 10.1111/jog.15718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Nana Ogino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan. Hauptthemen laut MEDLINE: Cancer Survivors, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
Ovarian tissue cryopreservation (OTC) is performed for fertility preservation in cancer patients undergoing chemotherapy. Although anti‐Müllerian hormone is used as a marker for ovarian reserve, serum levels do not always correlate with the number of follicles. Additionally, the follicle development stage most affected by chemotherapy is unclear. We examined the association between serum anti‐Müllerian hormone levels and the number of remaining primordial follicles after chemotherapy, as well as which follicle stage is most affected by chemotherapy before ovarian cryopreservation.
Methods
Thirty‐three patients who underwent OTC were divided into the chemotherapy ( n = 22) and non‐chemotherapy ( n = 11) groups; their ovarian tissues underwent histological examination. Pathological ovarian damage induced by chemotherapy was assessed. Ovarian volumes were estimated from weights. We compared the number of follicles at each developmental stage as a percentage of primordial follicles between the groups. The relationship between serum anti‐Müllerian hormone level and primordial follicle density was analyzed.
Results
The chemotherapy group had a significantly lower serum anti‐Müllerian hormone level, ovarian volume, and density of developing follicles than the non‐chemotherapy group. Serum anti‐Müllerian hormone levels correlated with primordial follicle density only in the non‐chemotherapy group. The chemotherapy group had significantly lower numbers of primary and secondary follicles.
Conclusions
Chemotherapy induces ovarian damage and follicle loss. However, serum anti‐Müllerian hormone level does not always reflect the number of primordial follicles after chemotherapy, and chemotherapy more significantly affects primary and secondary follicles than primordial follicles. Many primordial follicles remain in the ovary after chemotherapy, supporting OTC for fertility preservation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
- Department of Surgical Pathology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
ORCID-Profile: Nana Ogino, Yu Wakimoto, Hidetake Kamei, Atsushi Fukui
Zitieren
APA
Ogino, N., Wakimoto, Y., Nakagawa, K., Kamei, H., Fukui, A., Yoshiyasu, K., Hasegawa, A., Hirota, S., & Shibahara, H. (2023). Primordial follicles remaining in young cancer survivors who received chemotherapy. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15718
Vancouver
Ogino N, Wakimoto Y, Nakagawa K, Kamei H, Fukui A, Yoshiyasu K, et al. Primordial follicles remaining in young cancer survivors who received chemotherapy. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15718
BibTeX
@article{Ogino2023,
author = {Ogino, Nana and Wakimoto, Yu and Nakagawa, Kohei and Kamei, Hidetake and Fukui, Atsushi and Yoshiyasu, Kanako and Hasegawa, Akiko and Hirota, Seiichi and Shibahara, Hiroaki},
title = {Primordial follicles remaining in young cancer survivors who received chemotherapy},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2023},
doi = {10.1111/jog.15718}
}
EUVIMED